Polygenic Risk Stratification Combined With mpMRI to Identify Clinically Relevant Prostate Cancer
NCT ID: NCT06398639
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
1500 participants
INTERVENTIONAL
2024-05-07
2030-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* If genetic data related to prostate cancer used with MRI can identify higher-grade, potentially fatal prostate cancer
* What age a MRI is useful clinically for prostate cancer screening
* If deep learning methods used with MRI when the genetic risk of the man is known can more accurately predict significant cancers
Participants will:
* Get a prostate specific antigen (PSA) blood test
* Get an mpMRI
* Get the results of their genetic data to determine if they are considered high-, intermediate-, or low-risk for prostate cancer based on the trials genetic testing
* Follow-up for this trial based on the participants risk and findings from the PSA test and mpMRI
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Prostate cancer is the most commonly diagnosed cancer among men in the United States
* Prostate cancer screening using the marker prostate-specific antigen (PSA) is controversial
* PSA based screening is less effective, at least in part, because it rests on screening the entire population
* Polygenic risk scores stratify men based on their prostate cancer genetic predisposition and may improve population level screening programs by focusing on men with higher risk of disease and sparing low risk men
* It is critical that studies aiming to translate the development of an early-detection strategy are conducted within a diverse patient population to address prostate cancer mortality disparities
Study Design:
* Plan to accrue 1,500 participants from both established biobanks and primary care offices
* Participants will get an initial PSA screening blood test and an mpMRI
* Participants will have their polygenic risk score determined from genome-wide association study (GWAS) data
* Participant follow-up will be determined by PRS results, as well as if there are abnormal findings on their PSA screening and/or mpMRI
Objectives:
* To evaluate a screening algorithm to detect clinically relevant prostate cancer (Gleason score ≥7) using genetic data (PRS) to determine risk of cancer and mpMRI to identify men with higher grade cancer
* To determine optimal age to begin screening using PRS and mpMRI
* To determine if rare variants in DNA repair enzymes could help refine screening
* To determine if deep learning methods applied to mpMRI and informed by genetic risk can more accurately predict significant cancers
Prostate cancer screening using prostate specific antigen (PSA) is controversial. On the one hand, there is a reduction in prostate cancer mortality associated with screening. On the other, there is clear evidence that widespread and indiscriminate PSA based screening has led to over diagnosis and over treatment of prostate cancer. In part this is due to indiscriminate screening of all men, not just those at risk. Development and implementation of a screening strategy specifically targeting men at risk for potentially harmful prostate cancer, while sparing low risk men the burdens of screening, is urgently needed.
The investigators believe that integration of genetic testing and multiparametric MRI (mpMRI) will dramatically improve screening. Polygenic risk scores (PRS) have been developed to determine an individual's risk of prostate cancer and attempts have been made to create risk scores for clinically relevant disease. mpMRI has been established as an aid in differentiating clinically relevant from indolent prostate cancer.
Our scientific premise is that an integrated approach which leverages the strengths of both genetics and mpMRI will do more than simply risk stratify men into those at risk for and not at risk for prostate cancer; the investigators will stratify a population of men into those with and those without clinically relevant prostate cancer. The investigators hypothesize that genetic testing to first identify patients at risk of prostate cancer followed by mpMRI to determine who likely has clinically relevant disease represents an optimal strategy.
This study will determine if a polygenic risk score can be used in conjunction with mpMRI to identify Gleason score ≥7 cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Risk Cohort
Participants are placed into their arm after appropriate genetic testing has been conducted to determine their risk.
Polygenic Risk Score (PRS)
Participants will be put into PRS cohorts based on their genetic data.
All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score.
Intermediate Risk Cohort
Participants are placed into their arm after appropriate genetic testing has been conducted to determine their risk.
Polygenic Risk Score (PRS)
Participants will be put into PRS cohorts based on their genetic data.
All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score.
High Risk Cohort
Participants are placed into their arm after appropriate genetic testing has been conducted to determine their risk.
Polygenic Risk Score (PRS)
Participants will be put into PRS cohorts based on their genetic data.
All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Polygenic Risk Score (PRS)
Participants will be put into PRS cohorts based on their genetic data.
All participants enrolled into the study will receive a PSA screening test and an mpMRI, regardless of their polygenic risk score.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Estimated life expectancy of greater than 10 years.
* No history of prostate cancer.
* Participants must be between 40-69 years of age. This is the age at which screening for prostate cancer is recommended. This is due to younger patients not being at risk for the disease and older patients not benefiting from diagnosis.
* No biopsy for prostate cancer within the past 5 years.
* No prostate MRI within the past 5 years.
Exclusion Criteria
* Contraindication to biopsy such as uncorrectable bleeding or coagulation disorder.
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery.
* Unable to undergo an MRI.
40 Years
69 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Adam S. Kibel, MD
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Adam S. Kibel, MD
Chair, Department of Urology, Brigham Health & Dana-Farber Cancer Institute; DiNovi Family Distinguished Chair in Urology, Brigham and Women's Hospital; Elliott Carr Cutler Professor of Surgery, Harvard Medical School
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Adam S Kibel, MD, MHCM
Role: STUDY_CHAIR
Brigham and Women's Hospital
Peter Pinto, MD
Role: STUDY_CHAIR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Howard University Hospital
Washington D.C., District of Columbia, United States
National Cancer Institute
Bethesda, Maryland, United States
Walter Reed National Military Medical Center
Bethesda, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Brigham and Women's Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Pamela Coleman, MD
Role: primary
Peter A Pinto, MD
Role: primary
Gregory T Chesnut, MD
Role: primary
Keyan Salari, MD, PhD
Role: primary
Adam S Kibel, MD, MHCM
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23-564
Identifier Type: -
Identifier Source: org_study_id